Work

PD ‐1 Inhibitor (Sintilimab) Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Ovarian Cancer: A Case Report

Year: 2026

Type: article

Abstract: In a patient with advanced ovarian cancer showing limited response to paclitaxel-carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease-free status during olaparib-bevacizumab maintenance. This case provides a rationale for further investigation of PD-1 blockade as neoadjuvant therapy in carefully selected patients with suboptimal response to platinum-taxane chemotherapy.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.73598

Authors: Wang Zhenyan, Wang Yan

Institution: Affiliated Hospital of Qingdao University

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820